|
 |
Factor IXThis page contains recent news articles, when available, and an overview of Factor IX but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Overview: Factor IX (when available) Binds vitamin K and factor VIIIa. Cleaves the Arg-Ile bond in factor X to form active factor Xa. Plays a key role in blood coagulation and clotting. Injections of factor IX are used to treat hemophilia B, which is sometimes called Christmas disease. AlphaNine is injected to increase plasma levels of Factor IX and can temporarily correct this coagulation defect. For treatment of hemophilia (Christmas diseae) Mechanism Of Action: Cleaves the Arg-Ile bond in Factor X to form active factor Xa leading to coagulation and clotting. News Articles on Factor IX Biovitrum Advances Novel Factor VIII Long-Acting Hemophilia A Therapy into ... - Dec 17, 2009 ...with Biogen Idec and, thereby adding another significant collaboration project to the ongoing recombinant Factor IX Fc fusion (rFIXFc) clinical program. ... PR-USA.net (press release) Căn bệnh mang tên Christmas - Dec 24, 2009 ...(TNTT>) Bệnh Christmas được gá»?i là bệnh Hemophilia B, má»™t bệnh di truyá»?n chảy máu do thiếu nhân tố Factor IX. Trong y há»?c có hai loại bệnh di truyá»?n chảy ... Thanh Niên X-Linked Thrombophilia with a Mutant Factor IX (Factor IX Padua) - Oct 21, 2009 The level of the mutant factor IX protein in plasma was normal, but the clotting activity of factor IX from the proband was approximately eight times the ... New England Journal of Medicine (subscription) BAC BV enters licence agreement with Octapharma - Nov 10, 2009 Used for the treatment of Haemophilia B, BAC's anti-Factor IX CaptureSelect affinity ligand will be used in the large scale purification of recombinant ... Filtration + Separation Biogen Idec, Biovitrum To Further Study Hemophilia Treatment - Oct 19, 2009 Their treatment - fully recombinant factor IX Fc fusion protein - treats hemophilia B, caused by a deficiency or lack of that factor IX protein. ... Wall Street Journal Biogen Idec and Biovitrum Announce Decision to Advance Long-Acting Hemophilia ... - Oct 19, 2009 Hemophilia B occurs in about 1 in 25000 male births annually and is caused by having substantially reduced or no factor IX protein, which is needed for ... Reuters PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124(R)) in ... - Oct 26, 2009 Patients with hemophilia A and B lack adequate levels of Factor VIII (FVIII) or Factor IX (FIX) proteins due to mutations in their genetic code. ... Reuters Research and Markets: Routine and Special Coagulation Tests: Review of ... - Oct 30, 2009 Factor Assays * Introduction * Factor II * Factor V * Factor V Leiden * Factor VII * Factor VIII * Factor IX * Factor IXa * Factor X (Stuart Factor) ... Reuters Pass sensible reforms quickly - Oct 27, 2009 I am missing Factor IX, a clotting factor in my blood, and after I went off my parents' insurance I was fortunate enough to get on group plans with my ... In-Forum BAC Bio Affinity - Latest company news - Nov 2, 2009 2 November 2009 - BAC BV has entered into a licence agreement with Octapharma to use BAC's anti-Factor IX CaptureSelect affinity ligand in the large-scale ... Laboratory Talk Biovitrum Will Pay up to $533M for Swedish Orphan - Nov 10, 2009 Most advanced is a long-acting Factor IX Fc fusion protein for treating hemophilia B, which is in development with Biogen Idec Inc., of Cambridge, Mass. ... BioWorld Online Other News To Note - Nov 2, 2009 BAC BV, of Naarden, the Netherlands, entered a license agreement with Octapharma AG, of Lachen, Switzerland, to use BAC's anti-Factor IX CaptureSelect ... Therapeutics Daily (press release) (registration) Life, love, and bleeding hearts at hemophilia camp - Oct 26, 2009 Only 10 percent of registered patients are able to afford the needed factor VIII or factor IX products. It could mean a huge drain on the pocket. ... Philippine Star Research and Markets: The Competitor Analysis: Coagulation Factors Report ... - Oct 19, 2009 Key Topics Covered: * Coagulation Factor VIII * Coagulation Factor IX * Coagulation Factor VII * Von Willebrand Factor (vWF) * Fibrinogen * Coagulation ... Reuters Biovitrum to Acquire Swedish Orphan for Over $500M - Nov 5, 2009 In October Biovitrum and its partner Biogen Idec confirmed plans to advance the long-acting, fully recombinant Factor IX Fc fusion protein (rFIXFc) into a ... Genetic Engineering News (press release) Other News To Note - Nov 3, 2009 BAC BV, of Naarden, the Netherlands, entered a license agreement with Octapharma AG, of Lachen, Switzerland, to use BAC's anti-Factor IX CaptureSelect ... Therapeutics Daily (press release) (registration) Health Matters : What is Hemophilia ? - Nov 6, 2009 Hemophilia B, or Christmas disease, occurs because factor IX is deficient. These diseases are frequently genetic. In these situations, the symptoms usually ... PR-Inside.com (Pressemitteilung) Biogen Idec Reports Third Quarter 2009 Results - Oct 20, 2009 Biogen Idec and Biovitrum AB announced that they plan to advance the companies` long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into ... Reuters Cytoplasmic injection of circular plasmids allows targeted expression in ... - Oct 20, 2009 ...of mammalian cells, and resulted in persistent and high level expression of human factor IX and α1-antitrypsin in transfected mouse livers (8,9). ... BioTechniques.com Swedish Biovitrum Q3 '09 net profit declines - Oct 22, 2009 In October, Biovitrum and US sector player Biogen Idec Inc (NASDAQ: BIIB) announced their decision to advance their fully-recombinant Factor IX Fc fusion ... Trading Markets (press release) 1086. T Cell Responses to Canine Factor IX and AAV Capsid Antigens in... - Dec 27, 2006 Previous studies have shown successful correction of hemophilia B in dogs by muscle-directed gene delivery of canine F.IX (cF.IX) using an adeno-associated ... Nature.com Evidence of Multiyear Factor IX Expression by AAV-Mediated Gene … - Feb 20, 2006 Correspondence: Valder R. Arruda, Division of Hematology, 302F Abramson Research Center, The Children's Hospital of Philadelphia, 34th Street and Civic ... Nature.com … of liver in hemophilia by AAV-Factor IX and limitations imposed by... - Feb 12, 2006 Figure 1. F9 expression cassette and results of rAAV-F.IX in subjects E, F and G. (a) A schematic of the F9 (encoding F.IX) expression plasmid used to ... Nature.com 1055. High Levels of Human Factor IX Expression in Hemophilia B Mice ... - Jul 1, 2005 Various cell types have been targeted for expression of clotting factors in experimental models of hemophilia, with muscle and hepatocyte-directed gene ... Nature.com Hemophilia B - Symptoms, Diagnosis, Treatment of Hemophilia B - NY … - Mar 21, 2008 It is caused by a deficiency of a blood plasma protein called factor IX. Without enough factor IX, the blood cannot clot properly to control bleeding. ... New York Times FACTOR IX COMPLEX (Intravenous route, Injection route) - FAK-tor... - May 1, 2007 Factor IX is a protein produced naturally in the body. It helps the blood form clots to stop bleeding. Injections of factor IX are used to treat hemophilia ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Factor IX (Systemic). - Jul 28, 2005 Other commonly used names are Christmas factor, plasma thromboplastin component (PTC) , and prothrombin complex concentrate (PCC). Factor IX is a protein ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com … : Baxter Announces Recombinant Factor IX Development Program For … - Jan 7, 2008 Baxter Announces Recombinant Factor IX Development Program For Hemophilia B. from PR Newswire. Highbeam Research – FREE Trial. Pay-Per-View - PR Newswire - HighBeam Research Factor IX (Systemic).(Drug overview) - May 1, 2006 Other commonly used names are Christmas factor, plasma thromboplastin component (PTC) , and prothrombin complex concentrate (PCC). Factor IX is a protein ... Free with registration - USP DI-Volume II, Advice for the... - AccessMyLibrary.com Neose Receives Milestone Payment From Novo Nordisk on Factor IX … - May 24, 2007 Factor IX products are used in the treatment of Hemophilia B. Hemophilia B, ... The worldwide market for recombinant Factor IX was approximately $360 ... Genetic Engineering News - Genetic Engineering News (press release) Bloomberg Printer-Friendly Page - May 19, 2008 Factor IX products are used in the treatment of Hemophilia B. Hemophilia B is ... The worldwide market for recombinant Factor IX was approximately $360 ... Bloomberg GTC Biotherapeutics Obtains Licenses to Factor IX, Factor VIII and … - Dec 5, 2007 FRAMINGHAM, Mass. -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) has entered into a definitive agreement with ProGenetics, LLC, a private company based ... Free with registration - Business Wire - AccessMyLibrary.com Immune Responses to AAV Capsid: Are Mice Not Humans After All? - Feb 1, 2006 AAV-mediated factor IX gene transfer to skeletal muscle in patients with ... Induction of immune tolerance to coagulation factor IX antigen by in vivo ... Nature.com Coagulation; Factor IX recognition studied, need for factor XIa … - Aug 18, 2005 2005 AUG 18 - (NewsRx.com) -- According to recent research from the United States, factor XIa heavy chain is required for initial recognition of factor IX. ... Pay-Per-View - Blood Weekly - Factiva, from Dow Jones Baxter to tackle rarer form of hemophilia - Jan 8, 2008 ..."Our goal is to develop an unmodified version of recombinant Factor IX intended ... "A longer-acting Factor IX may translate into few required infusions, ... Pay-Per-View - Chicago Tribune - ProQuest Archiver … Develop Non-Injectable Dosage Form Of Factor IX To Control Bleeding - Dec 6, 2007 Nastech Pharmaceutical to develop an alternative dosage form of Factor IX protein which is currently administered by injection to control and prevent ... emaxhealth.com … of liver in hemophilia by AAV-Factor IX and limitations imposed by... - Feb 12, 2006 5 University of Pittsburgh Medical Center, Hemophilia Center of Western Pennsylvania, 3636 Boulevard of the Allies, Pittsburgh, Pennsylvania 15213, USA. ... Nature.com Coagulation; Factor IX recognition studied, need for factor XIa … - Aug 15, 2005 2005 AUG 15 - (NewsRx.com) -- According to recent research from the United States, factor XIa heavy chain is required for initial recognition of factor IX. ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones … of liver in hemophilia by AAV-Factor IX and limitations imposed by... - Feb 12, 2006 ...(a) Secretion of IFN- from the PBMCs of subject G after stimulation with 24 pools of peptides derived from AAV-2 capsid sequence. ... Nature.com Coagulation; Factor IX recognition studied, need for factor XIa … - Aug 15, 2005 ..."In contrast, inhibition of factor XIa cleavage of S2366 by factor IX (Ki 224±32 nM) ... "The results support a model in which factor IX binds initially to ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones … Biotherapeutics Expand Partnership to Include Coagulation Factor... - Jan 10, 2008 LFB Biotechnologies and GTC Biotherapeutics agreed to include a recombinant human coagulation factor IX program in their existing collaboration, ... Genetic Engineering News - Genetic Engineering News (press release) Neose gets milestone on Factor IX program.(Neose Technologies )(Brief... - Jun 4, 2007 Pennsylvania, USA-based Neose Technologies has received a milestone payment from Denmark's Novo Nordisk A/S under a license agreement entered into November ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Brain-damaged boy sues for negligence - Nov 13, 2008 There was no factor IX at Hurstville Community Co-operative Hospital where he was in care, the statement says, so George was transferred to the New ... Sydney Morning Herald Hemophilia B; Major genes share the control of factor IX antibody … - Apr 3, 2005 According to researchers in the United States, "we tested the hypothesis that the antibody response to human factor IX in mice is controlled by genetic ... Pay-Per-View - Medical Letter on the CDC & FDA - Factiva, from Dow Jones … Announces Filing of IND for Novel Recombinant Factor IX Product, - Nov 13, 2007 Our cost-effective manufacturing platform for Factor IX positions Inspiration to expand the ... Peptide of Factor IX Determines ... and CEO of Inspiration ... Pay-Per-View - PR Newswire - HighBeam Research Hemophilia B; Major genes share the control of factor IX antibody … - Mar 29, 2005 According to researchers in the United States, "we tested the hypothesis that the antibody response to human factor IX in mice is controlled by genetic ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Press Release: Inspiration Biopharmaceuticals Presents Data From … - Jul 11, 2007 Article: Baxter Announces Recombinant Factor IX Development ... PR Newswire; January 7, ... Article: FDA Approves New Factor IX Treatment for Hemophilia ... ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: AMT Starts Collaboration With St. Jude Children's … - Jul 15, 2008 Access to the Factor IX gene therapy program perfectly complements our gene therapy ... Article: FDA Approves New Factor IX Treatment for Hemophilia ... ... Pay-Per-View - PR Newswire - HighBeam Research Gene therapy gives hope to haemophiliacs - Mar 15, 2006 Although his levels of Factor IX eventually returned to what they were before the therapy, Dr Troedson said that since he received the treatment in October ... Sydney Morning Herald Hemophilia B; Major genes share the control of factor IX antibody … - Mar 28, 2005 According to researchers in the United States, "we tested the hypothesis that the antibody response to human factor IX in mice is controlled by genetic ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones Press Release: Wyeth Receives FDA Approval for New BeneFIX Features … - Mar 26, 2007 Article: FDA Approves New Factor IX Treatment for Hemophilia ... ... Article: Baxter Announces Recombinant Factor IX Development ... PR Newswire; January 7, ... Pay-Per-View - PR Newswire - HighBeam Research Study holds hope for next generation hemophilia treatment - Dec 24, 2008 While the past work increased the protein's activity (binding with factor IX), the current work dramatically increased the stability of factor VIII. ... Hindu Press Release: Pain Therapeutics Licenses Biotechnology To Treat Rare... - Mar 22, 2007 Article: Mice expressing defective human factor IX aid ... ... Article: Baxter Announces Recombinant Factor IX Development ... PR Newswire; January 7, ... Pay-Per-View - PR Newswire - HighBeam Research Hematology; New findings in the area of hematology described - Apr 25, 2005 Study 3: Mice expressing defective human factor IX aid hemophilia B research. ... The available mouse factor IX knockout models of hemophilia B (FIXKO ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones Arkansas Regulations - 292.540 Factor VIII, Factor IX and Cryoprecipit... - Apr 2, 2008 292.540 Factor VIII, Factor IX and Cryoprecipitate 7-1-07 Anti-hemophiliac Factor VIII is covered by the Arkansas Medicaid Program when administered in the ... Pay-Per-View - Arkansas Regulations - Loislaw Blood Clotting; Factor XIa examined, role of dimer in factor IX activa... - Sep 27, 2005 2005 SEP 27 - (NewsRx.com) -- A study from the United States has described the occurrence of factor XIa dimer in the activation of factor IX. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Revamped Wyeth drug gets EU go-ahead - Aug 21, 2007 ...'Recovery' is the level of circulating Factor IX in the blood after a certain period of time, with BeneFix achieving 28 per cent lower recovery than ... In-PharmaTechnologist.com Biovitrum and Syntonix sign factor IX accord.(Syntonix Pharmaceuticals... - Jan 30, 2006 Sweden's Biovitrum AB and Syntonix Pharmaceuticals of the USA have entered into a co-development and commercialization agreement for the latter's ... $4.95 - Pharma Marketletter - ECNext Hematology; Researchers provide details of new studies and findings... - Mar 10, 2005 Study 2: Mice expressing defective human factor IX aid hemophilia B research. ... The available mouse factor IX knockout models of hemophilia B (FIXKO ... Pay-Per-View - Blood Weekly - Factiva, from Dow Jones Wyeth Receives FDA Approval for New BeneFIX Features That Provide … - Mar 26, 2007 BeneFIX is a coagulation factor created using recombinant DNA technology to replace clotting factor IX to stop or prevent bleeding in people with hemophilia ... Free with registration - PR Newswire - AccessMyLibrary.com Patenting our genes - May 18, 2008 London-based BTG, a buyer of intellectual property, holds a bundle of patents which gives it control over the gene producing the protein Factor IX, ... guardian.co.uk Press Release: Biovitrum and Syntonix Enter Agreement for the Joint … - Jan 23, 2006 Article: Baxter Announces Recombinant Factor IX Development ... PR Newswire; January 7, ... Article: FDA Approves New Factor IX Treatment for Hemophilia ... ... Pay-Per-View - PR Newswire - HighBeam Research Hematology; Factor IX concentrates for treating hemophilia B lack TT... - Feb 7, 2005 2005 FEB 7 - (NewsRx.com & NewsRx.net) -- Factor IX concentrates for treating hemophilia B lack TT virus contamination. ... Pay-Per-View - Hematology Week - Factiva, from Dow Jones A 5-Month-Old Male With an Isolated Prolonged Partial Thromboplastin ... - Jun 7, 2007 The level of Factor IX was reported to be unquantifiable "possibly ... On repeat testing ( Table 1 ), the patient's Factor IX level was found to be markedly ... Medscape Hematology; Researchers provide details of new studies and findings... - Mar 7, 2005 Study 2: Mice expressing defective human factor IX aid hemophilia B research. ... The available mouse factor IX knockout models of hemophilia B (FIXKO ... Pay-Per-View - Health & Medicine Week - Factiva, from Dow Jones … the Joint Development and Commercialization of Recombinant Factor... - Jan 23, 2006 There is an increasing trend toward use of Factor IX for prophylaxis treatment ... The total market potential for Factor IX products is estimated to be in ... RedOrbit Inspiration Teams with Celtic in $35M Hemophilia Deal - Jan 10, 2008 While ramping up to begin clinical trials with its recombinant Factor IX product ... Inspiration's lead product, IB1001, is a recombinant Factor IX protein ... BioWorld Online - BioWorld Online AAV vectors and cardiovascular disease: Targeting TNF receptor in the... - Oct 18, 2007 This has been demonstrated for Factor IX in primates 6 and ovalbumin in mice. ... Successful transduction of liver in hemophilia by AAV-Factor IX and ... Nature.com Hematology; Researchers provide details of new studies and findings... - Mar 11, 2005 Study 2: Mice expressing defective human factor IX aid hemophilia B research. ... The available mouse factor IX knockout models of hemophilia B (FIXKO ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Biovitrum deal develops recombinant haemophilia treatment - Jan 26, 2006 The total market potential for Factor IX products is estimated to be in excess of $600 ... Its BeneFIX Coagulation Factor IX (Recombinant) and ReFacto ... DrugResearcher.com Bayer to pay up to $120M for Maxygen hemophilia program - Jul 2, 2008 It is caused by deficient or defective blood coagulation proteins, known as Factor VIII or Factor IX. About one in 10000 people are born with hemophilia A ... Bizjournals.com Hematology; New findings in the area of hematology described - Apr 30, 2005 Study 3: Mice expressing defective human factor IX aid hemophilia B research. ... The available mouse factor IX knockout models of hemophilia B (FIXKO ... Pay-Per-View - Obesity, Fitness & Wellness Week - Factiva, from Dow Jones Press Release: Wyeth Pharmaceuticals and Nautilus Biotech Announce … - Feb 5, 2007 Wyeth currently markets the only recombinant Factor IX product, ... Nautilus Biotech has created a portfolio ... gamma, Clotting Factor IX (in collaboration ... Pay-Per-View - PR Newswire - HighBeam Research Hematology; Factor IX concentrates for treating hemophilia B lack TT... - Feb 11, 2005 2005 FEB 11 - (NewsRx.com & NewsRx.net) -- Factor IX concentrates for treating hemophilia B lack TT virus contamination. ... Pay-Per-View - Drug Week - Factiva, from Dow Jones Gene Therapy Progress and Prospects: Fetal gene therapy – first... - Sep 1, 2005 The factor IX KO mice have no functional factor IX, and restoration of levels to 5% of ... Determination of factor IX blood levels allowed the monitoring of ... Nature.com Celtic Pharma announces Collaboration to Deliver Improved Therapies - Jan 9, 2008 ..."The market for Factor IX products has been growing historically at double digit rates and although medical practice has been shifting from on-demand to ... Web Services Journal - Web Services Journal BIOMEDICINE: Stanching the Flow -- Hines 307 (5713): 1171b -- Science - Feb 25, 2005 Injecting factor IX serves as treatment to stop bleeding, and restoring a ... In these experiments, the mice carried a mutation in their factor IX gene, ... Science Magazine - Science Magazine (subscription) UNL hemophilia research gets $10 million boost - Sep 12, 2005 The factor IX proteins are created in the liver, a sophisticated biochemical ... The grant will last five years, during which time the factor IX — which has ... Lincoln Journal Star … Develop a Non-Injectable Dosage Form of Factor IX to Control... - Dec 5, 2007 ..."Patients with hemophilia B, a result of deficiency in the Factor IX protein, ... Factor IX is a protein produced naturally in the body that helps the blood ... Free with registration - PR Newswire - AccessMyLibrary.com Neose Receives Research Milestone Payment from Novo Nordisk. - Aug 3, 2006 Factor IX products are used in the treatment of Hemophilia B. Hemophilia B, ... The worldwide market for recombinant Factor IX was approximately $350 ... Free with registration - Business Wire - AccessMyLibrary.com Press Release: Wyeth Pharmaceuticals and Nautilus Biotech Announce … - Feb 5, 2007 Wyeth currently markets the only recombinant Factor IX product, ... Nautilus Biotech has created a portfolio ... gamma, Clotting Factor IX (in collaboration ... Pay-Per-View - PR Newswire Europe - HighBeam Research Biovitrum Strengthens Its Relationship with Wyeth - Starts to Co... - Aug 8, 2007 BeneFIX uses recombinant DNA technology to replace clotting factor IX to stop ... People with hemophilia B are deficient in factor IX which is vital in the ... Free with registration - Business Wire - AccessMyLibrary.com Biovitrum and Syntonix set to begin phase I/IIa clinical trial of... - Mar 4, 2008 There is an increasing trend toward use of Factor IX for prophylaxis treatment ... The total market potential for Factor IX products is estimated to be in ... Lifescience-online Pain Therapeutics Licenses Biotechnology To Treat Rare Disorder - Mar 22, 2007 The key is to insert a healthy copy of the human gene for Factor IX, ... It also resulted in robust, persistent and normal levels of Factor IX in mice. ... Genetic Engineering News - Genetic Engineering News (press release) Decreased Bleeding Frequency With Secondary Prophylactic Use Of … - Dec 13, 2006 Hemophilia patients who have inhibitors (or neutralizing antibodies) against clotting-replacement factor VIII or factor IX experience severe morbidity due ... Medical News Today - Medical News Today (press release) Wyeth Receives Approval From European Medicines Agency For New … - Aug 26, 2007 People with haemophilia B are deficient in a key protein factor IX which is vital in the clotting mechanism to prevent bleeding. ... Medical News Today - Medical News Today (press release) Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to ... - Feb 5, 2007 Wyeth currently markets the only recombinant Factor IX product, BeneFIX(R) Coagulation Factor IX (Recombinant). As part of the agreement, Nautilus Biotech ... Free with registration - PR Newswire - AccessMyLibrary.com Biovitrum's and Syntonix's Novel Factor IXFc for Hemophilia B has … - Nov 24, 2008 The Fc fusion with factor IX is intended to prolong the effect of the compound, the goal being that patients will need less frequent prophylactic treatments ... marketwire.com … Feasibility Study to Develop a Non-Injectable Dosage Form of Factor... - Dec 5, 2007 ..."Patients with hemophilia B, a result of deficiency in the Factor IX protein, ... Factor IX is a protein produced naturally in the body that helps the blood ... Pay-Per-View - PR Newswire - HighBeam Research Wyeth Begins Marketing and Distributing BeneFIX in Europe - Jul 3, 2007 People with hemophilia B are deficient in a key protein- factor IX- which is vital in the clotting mechanism to prevent bleeding. ... RedOrbit Oncogenesis Following Delivery of a Nonprimate Lentiviral Gene... - May 11, 2005 A factor IX-deficient mouse model for hemophilia B gene therapy. Proc. Natl. Acad. Sci. USA 94: 11563–11566. | Article | PubMed | ChemPort | ... Nature.com Wyeth Begins Marketing and Distributing BeneFIX in Europe - Mar 7, 2007 People with hemophilia B are deficient in a key protein- factor IX- which is vital in the clotting mechanism to prevent bleeding. ... ITNews High Growth Reported for the World Blood Banking & Blood Products … - Jun 27, 2008 Plasma Fractions I-4 Fresh Frozen Plasma I-4 Albumin Fractions I-4 Factor VIII I-5 Factor IX and Factor IX Complex I-5 Fibrin/Thrombin I-5 Equipment, ... marketwire.com Interview with Dr Verma - Jan 27, 2005 We put it in a mouse defective for Factor IX and were very successful, ... And third, imagine with Factor IX – there's a wonderful new protein, ... Nature.com Renal vascular sclerosis is associated with inherited thrombophilias - Jun 7, 2006 The ASA-PCR control was the gene for factor IX. 26 Positive controls for the ... Factor IX control 25 5'-CTC CTG CAG CAT TGA GGG AGA TGG ACA TT-3' 5'-CTC ... Nature.com Removal of Empty Capsids from Type 1 Adeno-Associated Virus Vector … - Sep 25, 2005 A human clinical trial using rAAV2 expressing coagulation factor IX (up to 10 13 ... Evidence for gene transfer and expression of factor IX in haemophilia B ... Nature.com Inspiration Biopharmaceuticals Presents Data From Hemophilia Program ... - Jul 11, 2007 According to both presentations, Inspiration has identified structural properties of Factor IX that may improve the half-life and recovery compared to ... $4.95 - PR Newswire - ECNext Press Release: AMT Starts Collaboration With St. Jude Children's … - Jul 15, 2008 Access to the Factor IX gene therapy program perfectly complements our gene ... Amit Nathwani, M.D., Ph.D., who initiated his work on Factor IX while in ... Pay-Per-View - PR Newswire Europe - HighBeam Research Article: Recombinant Factor C assay.(in vitro diagnostic components:... - May 1, 2005 Article: Baxter Announces Recombinant Factor IX Development ... ... Evaluation Agency (EMEA) for its recombinant Factor IX, a clotting factor which is used ... Pay-Per-View - Medical Device Technology - HighBeam Research Redesigned Protein Accelerates Blood Clotting - Dec 22, 2008 While the past work increased the protein's activity (binding with factor IX), the current work dramatically increased the stability of factor VIII. ... Insciences Organisation FDA Approves Novo Nordisk, Inc. (NVO)'s NovoSeven(R) RT ( … - May 13, 2008 To stop bleeding episodes and manage their disease, people with severe hemophilia infuse themselves with clotting factor therapy-Factor VIII or Factor IX-to ... Lifescience-online Hemophilia; Embryonic stem cells treated with growth factor reverse … - Mar 7, 2005 The genetically altered mice lack the clotting substance factor IX, which in humans results in the hereditary bleeding disorder known as hemophilia B. This ... Pay-Per-View - Stem Cell Week - Factiva, from Dow Jones Press Release: AMT Makes Important Advance in the Development of its ... - Jun 10, 2008 The disease is caused by defective blood clotting due to an absence of clotting factor Factor IX. Gene therapy can be used to introduce the gene that ... Pay-Per-View - M2 Presswire - HighBeam Research Redesigned Protein Accelerates Blood Clotting - Dec 28, 2008 While the past work increased the protein's activity (binding with factor IX), the current work dramatically increased the stability of factor VIII. ... sciencedaily.com Biotech company makes deal with Bayer division - May 18, 2005 Factor IX levels in excess of 3 percent of normal levels are expected to substantially reduce spontaneous bleeding episodes. ... Small Times Haemophilia and inhibitors 1: Diagnosis and treatment - Jul 1, 2008 Treatment for haemophilia is usually by replacement of the missing clotting factor, that is, factor VIII for haemophilia A and factor IX for haemophilia B. ... Nursing Times Children's Hospital Big Give| Bristol News | This Is Bristol - Dec 7, 2008 ..."If they get factor IX in him he should be fine, unless he suffers head injuries and then we would have to take him into hospital." ... Bristol Evening Post AMT Makes Important Advance In The Development Of Its Gene Therapy … - Jun 11, 2008 The disease is caused by defective blood clotting due to an absence of clotting factor Factor IX. Gene therapy can be used to introduce the gene that ... Medical News Today - Medical News Today (press release) International Approvals: Cubicin, BeneFIX, Aricept - Sep 17, 2007 On August 20, the European Medicines Agency approved new enhancements for recombinant coagulation factor IX intravenous injection (nonacog alfa; BeneFIX, ... Medscape DOLLY AND ME: A TRUE STORYALAN TAYLOR INTERVIEWS … - Jul 9, 2006 She was a genetically-transformed clone, able to secrete the human protein, Factor IX, which makes the blood clot. If you don't have your own supply of ... Pay-Per-View - Sunday Herald - ProQuest Archiver Biogen Idec to Acquire Syntonix - Jan 5, 2007 Syntonix's lead product, FIX:Fc, is a proprietary long-acting factor IX product for the ... Hemophilia B, caused by mutations in the factor IX gene, ... Free with registration - AsiaPulse News - AccessMyLibrary.com Article: FACT SHEET - New Straits Times | HighBeam Research - FREE … - Feb 26, 2006 Haemophilia B, also known as Christmas Disease, is caused by a defective clotting factor known as factor IX. Haemophilia C, a rare occurence, is caused by a ... Pay-Per-View - New Straits Times - HighBeam Research Competitors by Product Report - Dec 20, 2008 Long-Acting Recombinant Factor IX; Long-Acting Recombinant Factor VIII ... Recombinant Human Coagulation Factor IX; Recombinant Human Coagulation Factor ... $75.00 - Revere Reports - Revere Southern Illinois University, US Journal reports outline Southern... - Dec 19, 2006 Study 1: Investigators publish new data in the report "Fatal hemorrhagic diathesis associated with mild factor IX deficiency in pl/J mice. ... Pay-Per-View - Life Science Weekly - Factiva, from Dow Jones Competitors by Product Report - Nov 8, 2008 Long-Acting Recombinant Factor IX; Long-Acting Recombinant Factor VIII ... Recombinant Human Coagulation Factor IX; Recombinant Human Coagulation Factor ... $75.00 - Revere - Alacra Store Competitors by Product Report - Dec 20, 2008 Long-Acting Recombinant Factor IX; Long-Acting Recombinant Factor VIII ... Recombinant Human Coagulation Factor IX; Recombinant Human Coagulation Factor ... $75.00 - Revere - Alacra Store Competitors by Product Report - Nov 8, 2008 Long-Acting Recombinant Factor IX; Long-Acting Recombinant Factor VIII ... Recombinant Human Coagulation Factor IX; Recombinant Human Coagulation Factor ... $75.00 - Revere Reports - Revere Competitors by Product Report - Aug 16, 2008 Long-Acting Recombinant Factor IX; Long-Acting Recombinant Factor VIII ... Recombinant Human Coagulation Factor IX; Recombinant Human Coagulation Factor ... $75.00 - Revere Reports - Revere Competitors by Product Report - Aug 16, 2008 Long-Acting Recombinant Factor IX; Long-Acting Recombinant Factor VIII ... Recombinant Human Coagulation Factor IX; Recombinant Human Coagulation Factor ... $75.00 - Revere - Alacra Store Biovitrum enters Nordic BeneFIX co-promo deal.(Brief article) - Aug 13, 2007 The agent uses recombinant DNA technology to replace clotting factor IX to stop or ... Sufferers are deficient in factor IX which is vital in the clotting ... $4.95 - Pharma Marketletter - ECNext Brand Names/Synonyms: Factor IX is also known by the following brand names and/or synonymsCoagulation factor IX precursor;Christmas factor;Plasma thromboplastin component;PTC; Benefix (Genetics Institute) Drug Category: Factor IX is categorized under the following by the FDA: Coagulants; Thrombotic Agents; hemostatics (20:12.16) Dosage Forms: LIQUID;POWDER FOR SOLUTION Absorption: Not Available Interactions: Not Available Chemical IUPAC Name: Human factor IX protein |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |